Preclinical studies in mice demonstrated the beneficial effect of supplementation with Bifidobacterium species on the anti-tumour efficacy of anti-PDL1 and anti-CTL4 [129,130], while antibiotics negatively affected the efficacy of PD-1 and CTL-4 antibody therapy in mice and patients [128]. This evidence concerns the gene SLC44A4 and neoplasm.